Pharmacogenomic Testing
Facilitate healthcare goals and gain personalized insights on how your DNA may be impacting medication use.
What is Pharmacogenomic Testing?
Pharmacogenomics (PGx) is the study of how genetic variations influence the way an individual responds to certain medications.
PGx now allows us to test for specific genetic attributes to predict whether a patient may have a normal response, a poor response, or a higher risk of side effects before prescribing a specific medication.
Testing a Range of Medicines Across Various Medical Specialties
The main medical categories tested are psychiatry, cardiology, gastroenterology, and pain medicine; however, insights into other medications are also included with our in-depth testing.
Our PGx report covers over 160 medications, and include detailed interpretations and recommendations with references to international PGx guidelines for each gene-drug pair, including suggestions of how to adjust dosages, and where appropriate, to select an alternative medication. Plus, if you have any questions, our small specialized team is always on standby to assist you.
PGx Testing Benefits
-
By testing certain genetic markers, the risk of possible side effects may be predicted even prior to starting the medication. This can help personalize dosage aand choice of medication.
-
PGx testing may help reduce some of the “trial and error” that may be involved in being prescribed different medications. Our testing provides you with information that can furteher assist in selecting an effective medication sooner, saving you time and money.
-
The test results presented in the report will assist you now and in the future, to decide if one of the covered medications is right for you.
Medications Covered
Our PGx test covers over 160 medicines.
Amitriptyline
Amoxapine
Amphetamine
Aripiprazole
Aripiprazole lauroxil
Atomoxetine
Brexpiprazole
Bupropion
Carbamazepine
Chlorpromazine
Citalopram
Clobazam
Clozapine
Clomipramine
Desipramine
Dextroamphetamine
Diazepam
Doxepin
Duloxetine
Escitalopram
Fluoxetine
Fluvoxamine
Haloperidol
Iloperidone
Imipramine
Lisdexamfetamine
Mirtazapine
Nortriptyline
Olanzapine
Oxcarbazepine
Paroxetine
Perphenazine
Pimozide
Protriptyline
Quetiapine
Risperidone
Sertraline
Thioridazine
Trimipramine
Venlafaxine
Vortioxetine
Pharmacogenetics (PGx) Resources
Recent Resarch
A landmark study has been published in The Lancet which shows that adverse drug reactions (ADRs) were reduced by 30% in individuals who had their drug treatment guided by pharmacogenomics.
Another study published in The National Center for Biotechnology Information, shows similar evidence. Adverse drug reactions are the 4th leading cause of death in the United States, so anything helping reduce this number is vital.
Guidelines & More
Certainty DNA ensures the clinical reporting of pharmacogenomic results is based, where possible, on the most published PGx guidelines, such as the Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Royal Dutch Pharmacists Association - Pharmacogenetics Working Group (DPWG). These guidelines are routinely updated, peer-reviewed, and published in relevant journals and can be accessed here.
The US Food and Drug Administration (FDA) has also recently published a list of medications with pharmacogenomic associations and recommendations, which are referenced, where relevant, in the PGx report.
Our Expertise
We are only partnered with laboratories that hold the highest accreditations, licesnes, and authorizations in genetic testing.
The clinical team for our PGx branch includes clinical pharmacologists, clinical pharmacists, clinical geneticists, and genetic counselors. Plus, our dedicated support team will always be here to answer any questions you may have.
Our reports are based on PGx guidelines and primary literature.
Less than 50% of patients are likely to have an adequate response to their first-line antidepressant.
A recent meta-analysis has shown that patients who received pharmacogenomic-guided antidepressant treatment were more likely to achieve symptom remission compared to patients without pharmacogenomic-guided treatment.
Peer-reviewed pharmacogenomic guidelines by international experts offer clinically actionable recommendations on specific gene-drug interactions covering many commonly prescribed psychotropic medications.
